Boji Medical Technology (300404.SZ) subsidiary Danyuan Diabetic Ointment has obtained the approval notice for drug clinical trials.

Boji Medical Technology (300404.SZ) announced that its wholly-owned subsidiary, Xinglin Traditional Chinese Medicine Technology (Guangzhou) Co., Ltd., recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for the "Danyuan Tangbi Soft Ointment". Approval Conclusion: According to the provisions of the Drug Administration Law of the People's Republic of China and relevant regulations, the clinical trial application for Danyuan Tangbi Soft Ointment, which was submitted on January 22, 2026, meets the relevant requirements for drug registration. With further improvement of the clinical trial protocol, the company has been granted permission to conduct clinical trials for the treatment of diabetic peripheral neuropathy.